B Cell Engineering and Tertiary Lymphoid Structure Induction via Biomaterials for Cancer Immunotherapy

BeaT-IT seeks to enhance cancer immunotherapy by optimizing B cell activation and tertiary lymphoid structure formation using nano-/biomaterials for improved tumor treatment outcomes.

Subsidie
€ 1.488.762
2022

Projectdetails

Introduction

Recent clinical evidence points to a potential new direction in immuno-oncology: utilizing B cells and B cell-associated tertiary lymphoid structures (TLS). B cells display diverse immunological actions, including antibody production, antigen presentation, cytokine secretion, and TLS induction.

Dual Role of B Cells

They have a dual role: they can initiate and reinforce anti-cancer immunity, but B cells can also acquire regulatory phenotypes.

Objectives

To open up a new immunotherapeutic paradigm, I aim to understand how to optimally activate B cells, using nano-/biomaterials which load and precisely release a variety of agents to stimulate B cells and to suppress B cell regulatory phenotypes.

Scaffold Manufacturing

Furthermore, I will manufacture porous scaffolds based on injectable microgels or via 3D printing with microgel fibers to induce TLS formation. The scaffolds with tunable porosity will allow:

  • B cells and other immune/stromal cells to infiltrate, arrange, and expand
  • Soluble factors to diffuse

Moreover, the scaffolds can be easily functionalized with different chemical cues to stimulate B cells for TLS formation, such as CXC-chemokine ligand 13 and interleukin-7. This will help us understand TLS induction.

Ex Vivo and In Vivo Studies

Importantly, I will use ex vivo engineered TLS to study what microenvironmental factors influence their functionality. Subsequently, in vivo formation of B cell-associated TLS will be induced by the scaffolds.

Combined Therapies

B cell activation and TLS induction will be combined for tumor therapy, and the potential abscopal effect of the treatment to address metastases will be studied. The materials will be further combined with checkpoint inhibitors and chemotherapy to reach synergism.

Testing in Patient-Derived Tumors

In addition, the new therapeutic strategies will be tested in patient-derived tumors established in humanized mice.

Conclusion

BeaT-IT aims to understand optimal B cell activation and TLS formation with nano-/biomaterials to establish a new direction in immuno-oncology, which is anticipated to realize an upcoming breakthrough in cancer immunotherapy.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.488.762
Totale projectbegroting€ 1.488.762

Tijdlijn

Startdatum1-7-2022
Einddatum30-6-2027
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • UNIVERSITAETSKLINIKUM AACHENpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Consolid...

Engineering B cells to fight cancer

This project aims to develop a novel cancer immunotherapy using engineered B cells to enhance anti-tumor responses through targeted gene integration and localized immune activation.

€ 1.996.250
ERC Consolid...

Targeting tertiary lymphoid structures using magneto-margination

The project aims to develop injectable superparamagnetic particles for non-invasive mapping and thermal destruction of tertiary lymphoid structures to improve diagnosis and treatment of chronic inflammation and cancer.

€ 1.970.480
ERC Proof of...

Engineering and Delivering B Cells Using Biomaterials against Breast Cancer

END-BC aims to enhance B cell adoptive cell therapy for breast cancer using novel biomaterials to improve efficacy, reduce side effects, and lower treatment costs.

€ 150.000
ERC Advanced...

Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapies

The TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies.

€ 2.500.000
ERC Starting...

Polyclonal anti-tumor immunity by engineered human T cells

This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.

€ 1.812.500

Vergelijkbare projecten uit andere regelingen

EIC Transition

Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell Reprogramming

The Repro-TIL project aims to enhance tumor-reactive TIL expansion for more effective immunotherapy in solid tumors, paving the way for improved treatment outcomes and commercialization.

€ 2.480.367
EIC Transition

RESTORING IMMUNITY CONTROL OF GI CANCERS

TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.

€ 2.007.750